Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Summary

This is an open-label phase I/II study evaluating the addition of ebastine to docetaxel in the treatment for metastatic castration resistant prostate cancer. Patients will be randomized in a 2:1 fashion to receive ebastine daily during and after treatment with a maximum of 10 courses of docetaxel. The primary endpoint is change in the profile of urinary and blood lipids to indicate absorption and possible efficacy of ebastine. Secondary endpoints include PSA response and radiologic progression free survival.

Timeline

Start

2024-06-20

Primary completion

2026-12-01

Completion

2027-12-01

Publications

• Orum K, Stormoen DR, Lauritsen J, Rohde M, Jaattela M, Pappot H. An example of drug repurposing: ebastine in combination with docetaxel as a treatment for metastatic castration-resistant prostate cancer-the EXUROC prostate study, a clinical trial protocol. BMC Urol. 2025 Jul 4;25(1):154. doi: 10.1186/s12894-025-01837-0.

Drugs

Indications